Clinically meaningful improvement in work productivity loss in active psoriatic arthritis : post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials
OBJECTIVES: To determine the proportion of patients in Phase 3 studies (SPIRIT-P1 and SPIRIT-P2) who achieved minimal clinically important difference (MCID) for work productivity loss and activity impairment domains of Work Productivity and Activity Impairment Specific Health Problem (WPAI-SHP) questionnaire.
METHODS: In the SPIRIT-P1 study, comprising a 24-week double-blind treatment period, biologic-naive patients with active psoriatic arthritis (PsA) were randomised to ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) (starting dose of 160 mg), adalimumab 40 mg every 2 weeks (ADAQ2W), or placebo. SPIRIT-P2 enrolled tumour necrosis factor inhibitor (TNFi)-experienced patients who were randomised to receive IXEQ4W, IXEQ2W or placebo for 24 weeks of double-blind treatment. In this post-hoc analysis, we investigated the proportion of patients in SPIRIT-P1 and P2 studies who achieved 15% improvement in work productivity loss and 20% improvement in activity impairment domains of WPAI-SHP during double- blind treatment period.
RESULTS: In SPIRIT-P1, at Week 24, 57.1% and 55.8% of biologic-naive patients on IXEQ4W and ADAQ2W respectively, achieved MCID estimates for work productivity loss compared to 25.6% of patients treated with placebo. The proportion of ixekizumab- and adalimumab-treated patients achieving MCIDs for activity impairment were significantly higher (IXEQ4W: p<0.001; ADAQ2W: p=0.001) com- pared to placebo-treated patients at Week 24. In SPIRIT-P2, significantly more TNFi-experienced patients on IXEQ4W (p<0.001) achieved MCIDs compared to placebo at Week 24.
CONCLUSIONS: Treatment with ixekizumab was associated with clinically meaningful improvements in WPAI-SHP domains in biologic-naive and TNFi- experienced patients with active PsA.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
Clinical and experimental rheumatology - 38(2020), 6 vom: 26. Nov., Seite 1227-1230 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tillett, William [VerfasserIn] |
---|
Themen: |
Adalimumab |
---|
Anmerkungen: |
Date Completed 08.12.2020 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM310344964 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310344964 | ||
003 | DE-627 | ||
005 | 20231225135907.0 | ||
007 | tu | ||
008 | 231225s2020 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n1034.xml |
035 | |a (DE-627)NLM310344964 | ||
035 | |a (NLM)32452352 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tillett, William |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinically meaningful improvement in work productivity loss in active psoriatic arthritis |b post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 08.12.2020 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVES: To determine the proportion of patients in Phase 3 studies (SPIRIT-P1 and SPIRIT-P2) who achieved minimal clinically important difference (MCID) for work productivity loss and activity impairment domains of Work Productivity and Activity Impairment Specific Health Problem (WPAI-SHP) questionnaire | ||
520 | |a METHODS: In the SPIRIT-P1 study, comprising a 24-week double-blind treatment period, biologic-naive patients with active psoriatic arthritis (PsA) were randomised to ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) (starting dose of 160 mg), adalimumab 40 mg every 2 weeks (ADAQ2W), or placebo. SPIRIT-P2 enrolled tumour necrosis factor inhibitor (TNFi)-experienced patients who were randomised to receive IXEQ4W, IXEQ2W or placebo for 24 weeks of double-blind treatment. In this post-hoc analysis, we investigated the proportion of patients in SPIRIT-P1 and P2 studies who achieved 15% improvement in work productivity loss and 20% improvement in activity impairment domains of WPAI-SHP during double- blind treatment period | ||
520 | |a RESULTS: In SPIRIT-P1, at Week 24, 57.1% and 55.8% of biologic-naive patients on IXEQ4W and ADAQ2W respectively, achieved MCID estimates for work productivity loss compared to 25.6% of patients treated with placebo. The proportion of ixekizumab- and adalimumab-treated patients achieving MCIDs for activity impairment were significantly higher (IXEQ4W: p<0.001; ADAQ2W: p=0.001) com- pared to placebo-treated patients at Week 24. In SPIRIT-P2, significantly more TNFi-experienced patients on IXEQ4W (p<0.001) achieved MCIDs compared to placebo at Week 24 | ||
520 | |a CONCLUSIONS: Treatment with ixekizumab was associated with clinically meaningful improvements in WPAI-SHP domains in biologic-naive and TNFi- experienced patients with active PsA | ||
650 | 4 | |a Clinical Trial, Phase III | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 7 | |a Antirheumatic Agents |2 NLM | |
650 | 7 | |a Dermatologic Agents |2 NLM | |
650 | 7 | |a Adalimumab |2 NLM | |
650 | 7 | |a FYS6T7F842 |2 NLM | |
700 | 1 | |a Lin, Chen-Yen |e verfasserin |4 aut | |
700 | 1 | |a Trevelin Sprabery, Aubrey |e verfasserin |4 aut | |
700 | 1 | |a Birt, Julie A |e verfasserin |4 aut | |
700 | 1 | |a Kavanaugh, Arthur |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 38(2020), 6 vom: 26. Nov., Seite 1227-1230 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2020 |g number:6 |g day:26 |g month:11 |g pages:1227-1230 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 38 |j 2020 |e 6 |b 26 |c 11 |h 1227-1230 |